Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Peyer James						2. Issuer Name and Ticker or Trading Symbol Sensei Biotherapeutics, Inc. [SNSE]									tionship of Repor all applicable) Director		3	1 0%	Owne	wner	
(Last) C/O SEN	`	rst) (I HERAPEUTICS	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/10/2022 Officer (give title below) below) Officer (give title below)												ecify				
1405 RESEARCH BLVD. SUITE 125					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	ILLE M	D 2	0850												Form filed by One R Form filed by More the Person						
(City)	(Si	tate) (2	Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,			3. Transaction Disposed Of (D) (Instr. 3, 4 5)				ed (A) or str. 3, 4 ar	or 5. Amount of Securities Beneficially Owned Follow Reported			Form: Direct (D) or Indirect		Indirect Beneficial Ownership			
									Code	v	Amount	(A) oi (D)	Price	Tr	ransac nstr. 3	tion(s)	(Instr. 4)				
Common	Stock			01/10/2	022				P		10,000	A	\$5.28	3(1)	4,92	9,413		I ⁽²⁾ See footnote ⁽²⁾			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any	eemed ition Date, h/Day/Year)		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exerc ation D h/Day/`		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Deriv Secu	Price of erivative ecurity estr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownersh Form: Direct (D or Indire (I) (Instr.	nip o E) C ct (i	1. Nature of Indirect Beneficial Ownership Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Number of Shares								

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.25 to \$5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
- 2. These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares

/s/ Erin Hoffert, Attorney-in-

Fact

** Signature of Reporting Person

01/11/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.